Late-Breaking Science announced for #ISC25
#ISC25 will present the results from 19 late-breaking science studies during the Main Events each day.
Opening Main Event
11 a.m.-12:35 p.m. | Wednesday, Feb. 5
LB1 | Procedural, Safety and Functional Outcomes Following Minimally Invasive Surgery for Deep and Lobar Intracranial Hemorrhages: MIND Study Results
David Fiorella, Stony Brook University Hospital, Stony Brook, New York
LB2 | TransRadial Versus Transfemoral Arterial Access for Cerebral Angiography
Wei Ni, Huashan Hospital, Fudan University, Shanghai, China
LB3 | Endovascular Therapy Plus Best Medical Treatment Versus Best Medical Treatment Alone for Medium Distal Vessel Occlusion Stroke: The DISTAL Trial
Marios Psychogios, University Hospital Basel, Basel, Switzerland
LB4 | Endovascular Treatment to Improve Outcomes for Medium Vessel Occlusions: The ESCAPE-Mevo Trial
Mayank Goyal, University of Calgary, Calgary, AB, Canada
LB47 | Mechanical Thrombectomy in Acute Ischemic Stroke Related to a Distal Occlusion: Interim Analysis of the DISCOUNT Randomized Controlled Trial
Frédéric Clarençon, Pitié-Salpêtrière Hospital, Paris, France
Thursday Main Event
11 a.m.-12:30 p.m. | Thursday, Feb. 6
LB16 | TRANScranial Direct Current Stimulation for Post-Stroke Motor Recovery: A Phase 2 Study (TRANSPORT2) Main Results
Wayne Feng, Duke University School of Medicine, Chapel Hill, North Carolina
LB17 | Intensive Blood Pressure Lowering After Thrombectomy in Ischemic Stroke Patients: A Randomized Clinical Trial
Xuening Zhang, West China Hospital, Chendu, China
LB18 | Coordinated, Collaborative, Comprehensive, Family-Based, Integrated, Technology-Enabled Post-Stroke Care
George Howard, University of Alabama-Birmingham, Birmingham, Alabama
LB19 | The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial 2 Final Results
Ken Butcher, University of New South Wales, Randwick, NSW, Australia
LB20 | Atorvastatin Treatment and Rebleeding in Cerebral Cavernous Malformations: A Randomized, Placebo-Controlled, Double-Blinded Clinical Trial
Issam A. Awad, University of Chicago Medical Center, Chicago, Illinois
Closing Main Event
11 a.m.-1:05 p.m. | Friday, Feb. 7
LB37 | Effects of Direct Oral Anticoagulants Versus No Anticoagulation in the Prevention of Stroke in Intracerebral Haemorrhage Survivors With Atrial Fibrillation (PRESTIGE-AF) Trial
Roland Veltkamp, Imperial College London, London, United Kingdom
LB38 | Intra-Arterial Tenecteplase Thrombolysis for Acute LVO After Successful Mechanical Thrombectomy Recanalization (ANGEL-TNK) — A Multicenter, Prospective, Randomized, Open-Label, Blinded Endpoint Trial
Miao Zhongrong, Beijing Tiantan Hospital, Beijing, China
LB39 | The Optimal Dosage of Adjunctive Intra-Arterial Tenecteplase Following Successful Endovascular Thrombectomy in Patients With Large Vessel Occlusion Acute Ischemic Stroke (DATE) Trail
Xianhua Hou, The First Affiliated Hospital, Army Medical University, Chongqing, China
LB40 | Extending the Time Window for Tenecteplase by Effective Reperfusion of Penumbral Tissue in Patients With Large Vessel Occlusion (ETERNAL-LVO): A Multicenter, Prospective, Open-Label, Blinded Endpoint, Controlled, Phase 3, Superiority Trial
Vignan Yogendrakumar, The Ottawa Hospital, Ottawa, ON, Canada
LB41 | Treatment With Intravenous Alteplase in Ischemic Stroke Patients With Onset Time Between 4.5 And 24 Hours
Min Lou, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China
LB42 | Intra-Arterial Alteplase for Acute Ischemic Stroke After Mechanical Thrombectomy (PEARL): A Multicenter Randomized Trial
Yamei Tang, Sun Yat-sen Memorial Hospital, Guangzhou, China
LB43 | A Randomized Controlled Trial of Antithrombotic Therapy in Ischemic Stroke Patients With Non-Valvular Atrial Fibrillation and Atherosclerosis: The ATIS-NVAF Trial
Shuhei Okazaki, NHO Osaka National Hospital, Osaka, Japan
LB44 | Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus (LAMP): A Randomized Clinical Trial
Huili Zhu, The First Affiliated Hospital of Jinan University, Guangzhou, China
LB45 | BXOS110 for Acute Ischemic Stroke Treatment (BEST): A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial
Yarong Ding, Beijing Tiantan Hospital, Beijing, China
See Online Program Planner for more information.
